Amancio, Gabriela de Cássia SousaGuimarães, Andrea GrabeHaikel, DridiMoreau, JohanBarcellos, Neila Marcia SilvaLacampagne, AlainMatecki, StefanCazorla, Olivier2019-04-152019-04-152017AMANCIO, D. de C. S. et al. Effect of pyridostigmine on in vivo and in vitro respiratory muscle of mdx mice. Respiratory Physiology & Neurobiology, v. 243, p. 107-114, set. 2017. Disponível em: <https://www.sciencedirect.com/science/article/pii/S1569904817300691?via%3Dihub>. Acesso em: 25 fev. 2019.15699048http://www.repositorio.ufop.br/handle/123456789/11012The current work was conducted to verify the contribution of neuromuscular transmission defects at the neuromuscular junction to Duchenne Muscular Dystrophy disease progression and respiratory dysfunction. We tested pyridostigmine and pyridostigmine encapsulated in liposomes (liposomal PYR), an acetylcholinesterase inhibitor to improve muscular contraction on respiratory muscle function in mdx mice at different ages. We evaluated in vivo with the whole-body plethysmography, the ventilatory response to hypercapnia, and measured in vitro diaphragm strength in each group. Compared to C57BL10 mice, only 17 and 22 month-old mdx presented blunted ventilatory response, under normocapnia and hypercapnia. Free pyridostigmine (1 mg/kg) was toxic to mdx mice, unlike liposomal PYR, which did not show any side effect, confirming that the encapsulation in liposomes is effective in reducing the toxic effects of this drug. Treatment with liposomal PYR, either acute or chronic, did not show any beneficial effect on respiratory function of this DMD experimental model. The encapsulation in liposomes is effective to abolish toxic effects of drugs.en-USrestritoDuchenne muscular dystrophyPyridostigmine bromideRespiratory functionDiaphragm contractilityPletysmographyArtigo publicado em periodicohttps://www.sciencedirect.com/science/article/pii/S1569904817300691